pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
910
stories
24d
Do you need oncology experience to land an oncology job?
biospace
24d
Incyte cuts early-stage cancer drug to focus on next-gen programs
biospace
24d
‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrence
fiercebiotech
24d
A neglected issue in pedestrian, biker deaths
stat
24d
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
biospace
24d
Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
fiercebiotech
24d
STAT+: FDA expert panel recommends against approval of Capricor’s Duchenne drug
stat
24d
Opinion: The VA could help America win the biotechnology race with China
stat
24d
STAT+: In the biotech industry, a most-wanted fugitive was long hiding in plain sight
stat
24d
Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera
fiercebiotech
24d
STAT+: American Diabetes Association, facing calls for resignations, asks for patience
stat
25d
GSK prepares for patent cliff with $2.5B cost-cutting plan
biopharma dive
25d
GSK shares rise as $2.5B cost-cutting plan unveiled
biospace
25d
STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials
stat
25d
STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
stat
25d
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
25d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
25d
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
25d
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
biospace
25d
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
fiercebiotech
25d
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
25d
Guardant Health taps Patrick Dempsey for emotional colorectal cancer awareness video
fiercebiotech
25d
GSK partner Hansoh reports another phase 3 win for priority ADC
fiercebiotech
26d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
26d
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
26d
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
26d
Legend CEO Ying Huang resigns; Carvykti chief named interim leader
endpoints
26d
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
26d
Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease
endpoints
26d
FDA approves Freenome colorectal cancer blood test to be marketed by Abbott
fiercebiotech
← prev
page 9 of 31
next →
